報價延遲最少15分鐘:2025/04/15 14:48 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
61.8 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.34/-1.49
|
|
企業價值
3.81B
|
| 資產負債 |
|
每股賬面淨值
0.34
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
130.13M
|
|
每股收益
0.69
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/15 14:48 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States. |